Early transmission and case fatality of Ebola virus at the index site of the 2013-16 west African Ebola outbreak: a cross-sectional seroprevalence survey. by Timothy, Joseph WS et al.
Timothy, JosephWS; Hall, Yper; Akoi-Bor, Joseph; Diallo, Boubacar;
Tipton, Thomas RW; Bower, Hilary; Strecker, Thomas; Glynn, Ju-
dith R; Carroll, Miles W (2019) Early transmission and case fatality
of Ebola virus at the index site of the 2013-16 west African Ebola
outbreak: a cross-sectional seroprevalence survey. The Lancet. Infec-
tious diseases. ISSN 1474-4457 DOI: https://doi.org/10.1016/s1473-
3099(18)30791-6
Downloaded from: http://researchonline.lshtm.ac.uk/4651602/
DOI: 10.1016/s1473-3099(18)30791-6
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: http://creativecommons.org/licenses/by/2.5/
www.thelancet.com/infection   Published online February 21, 2019   http://dx.doi.org/10.1016/S1473-3099(18)30791-6 1
Articles
Lancet Infect Dis 2019
Published Online 
February 21, 2019 
http://dx.doi.org/10.1016/
S1473-3099(18)30791-6
See Online/Comment 
http://dx.doi.org/10.1016/
S1473-3099(19)30055-6
*Contributed equally
London School of Hygiene & 
Tropical Medicine, London, UK 
(J W S Timothy PhD, 
H Bower MSc, J R Glynn PhD); 
Research and Development 
Institute, National Infection 
Service, Public Health England, 
Porton Down, Salisbury, UK 
(Y Hall PhD, T R W Tipton PhD, 
M W Carroll PhD); Public Health 
England/Tropical Medicine 
Institute Berlin Reference 
Laboratory, Guéckédou, Guinea 
(J Akoi-Boré MSc); World Health 
Organization, Regional Office 
for Africa, Brazzaville, Republic 
of Congo (B Diallo MD); 
and Institute of Virology, 
Philipps University, Marburg, 
Germany (T Strecker PhD)
Correspondence to: 
Dr Joseph WS Timothy, London 
School of Hygiene & Tropical 
Medicine, London  WC1E 7HT, UK 
joseph.timothy@lshtm.ac.uk
Early transmission and case fatality of Ebola virus at the 
index site of the 2013–16 west African Ebola outbreak: 
a cross-sectional seroprevalence survey
Joseph W S Timothy, Yper Hall, Joseph Akoi-Boré, Boubacar Diallo, Thomas R W Tipton, Hilary Bower, Thomas Strecker, Judith R Glynn*, 
Miles W Carroll*
Summary
Background To date, epidemiological studies at the index site of the 2013–16 west African Ebola outbreak in Meliandou, 
Guinea, have been restricted in their scope. We aimed to determine the occurrence of previously undocumented 
Ebola virus disease (EVD) cases and infections, and to reconstruct transmission events.
Methods This cross-sectional seroprevalence survey of the adult population of Meliandou used a highly specific oral 
fluid test and detailed interviews of all households in the village and key informants. Each household was interviewed, 
with all members prompted to describe the events of the outbreak, any illness within the household, and possible 
contact with suspected cases. Information for deceased individuals was provided by relatives living in the same 
household. Symptoms were based on Ebola virus Makona variant EVD case definitions (focusing on fever, vomiting, 
and diarrhoea). For antibody testing, we used an Ebola virus glycoprotein IgG capture enzyme immunoassay 
developed from a previously validated assay. A maximum exposure level was assigned to every participant using a 
predetermined scale. We used a generalised linear model (logit function) to estimate odds ratios for the association of 
sociodemographic variables and exposure level with Ebola virus infection. We adjusted estimates for age and 
maximum exposure, as appropriate.
Findings Between June 22, and July 9, 2017, we enrolled 237 participants from 27 households in Meliandou. 
Two households refused to participate and one was absent. All adults in participating households who were present 
for the interview provided an oral fluid swab for testing, of which 224 were suitable for analysis. In addition to the 
11 EVD deaths described previously, on the basis of clinical description and oral fluid testing, we found two probable 
EVD deaths and eight previously unrecognised anti-Ebola virus IgG-positive survivors, including one who had mild 
symptoms and one who was asymptomatic, resulting in a case fatality of 55·6% (95% CI 30·8–78·5) for adults. 
Health-care work (adjusted odds ratio 6·64, 1·54–28·56; p=0·001) and level of exposure (odds ratio adjusted for linear 
trend across five levels 2·79, 1·59–4·883; p<0·0001) were independent risk factors for infection.
Interpretation Ebola virus infection was more widespread in this spillover population than previously recognised 
(21 vs 11 cases). We show the first serological evidence of survivors in this population (eight anti-Ebola virus IgG 
seropositive) and report a case fatality lower than previously reported (55·6% vs 100% in adults). These data show the 
high community coverage achievable by using a non-invasive test and, by accurately documenting the beginnings of 
the west African Ebola virus outbreak, reveal important insight into transmission dynamics and risk factors that 
underpin Ebola virus spillover events.
Funding US Food and Drug Administration, Wellcome Trust, and German Research Council.
Copyright © 2019 World Health Organization; licensee Elsevier. This is an Open Access article published under the 
CC BY 3.0 IGO license which permits unrestricted use, distribution, and reproduction in any medium, provided the 
original work is properly cited. In any use of this article, there should be no suggestion that WHO endorses any 
specific organisation, products or services. The use of the WHO logo is not permitted. This notice should be preserved 
along with the article’s original URL.
Introduction
Ebola virus disease (EVD) is a haemorrhagic fever 
characterised by severe, multisystem disease, and a high 
case fatality.1 Ebola viruses are zoonotic pathogens 
circulating among sylvatic species with scarce direct 
contact with humans.2–4 Only 27 distinct zoonotic spillover 
events among human populations have been identified 
since the discovery of the virus in 1976.5 Owing to the 
inherent difficulty of surveillance in remote locations, 
many outbreak investigations rely on retrospective 
detection, and can overlook mild EVD clinical pre- 
sentations.6,7 Investigation has also been hampered by the 
absence of reliable immunological tools to quantify past 
infection.8,9 Because of these challenges, there are still 
knowledge gaps in the natural history and transmission 
patterns of Ebola virus during early spillover events.
For more on spillover events see 
https://www.cdc.gov/vhf/ebola/
history/chronology.html
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Although severe clinical manifestations dominate 
during human EVD outbreaks, both minimally symp- 
tomatic and asymptomatic infections occur, particularly 
among contacts of cases.7,10,11 Evidence for the existence of 
sub-symptomatic cases includes Ebola virus PCR analysis 
of contacts of patients in the 1996 Gabon outbreak, who 
showed signs of viral replication in their blood in the 
absence of EVD symptoms.12 Two surveys7,10 done in west 
Africa suggested that asymptomatic infections are 
infrequent (2·6% and 7·5% among contacts). The larger 
of these studies7 reliably identified asymptomatic 
infections using non-invasive oral fluid sampling and a 
novel anti-Ebola virus IgG capture assay with high 
specificity (100%, 95% CI 98·9–100) and sensitivity 
(95·9%, 89·8–98·9).
The true incidence of subclinical infections and their 
contribution to transmission dynamics are not fully 
understood.13,14 Surveys8,15,16 have reported seroprevalence 
of 0–46% for Ebola virus infection in endemic areas and 
up to 24% in regions with no previously documented 
exposure to the virus. The relative contribution of true 
asymptomatic infections,17 exposure to unrecognised 
filoviruses, or immunoassay cross-reactivity to these 
findings is not clear.13 Comprehensive documentation of 
Ebola virus spillover incidents will inform understanding 
on the role of different disease states and the nature of 
viral spread among exposed communities in the early 
stages of an outbreak.
The Ebola virus Makona variant (Zaire species), which 
emerged from Guinea in 2013, caused the largest 
recorded outbreak of any Ebola virus species in humans 
(28 625 cases and 11 325 deaths notified)18 and stemmed 
from a single spillover event in the village of Meliandou, 
Guéckédou prefecture—for which 11 cases were reported, 
all of whom died.19–21 This study aims to provide a 
quantitative description of these initiating events in the 
absence of any previous serological or diagnostic analyses 
at this location.19,22
Methods
Study design and participants
We sought to enrol all family members residing in 
Meliandou who were aged 18 years or older at the time of 
the study. Meliandou is a rural village of 30 households 
living in 75 buildings, all belonging to the Kissi ethno-
linguistic group. The village is encircled by a 100–200 m 
perimeter of forest and is about 12 km by uneven road 
from the nearest major urban centre (Guéckédou). All 
residents were checked by village leaders and local health-
care workers before registration to confirm that they had 
been resident during the period of the outbreak in this 
area (December, 2013, to March, 2014). Information on 
EVD exposure and symptoms was collected retro- 
spectively. Interviews were done for all households on the 
basis of qualitative and quantitative approaches used in 
Sierra Leone, as described previously.7,23 Each household 
was interviewed as a group led by Kissi-speaking field 
staff using a semi-structured approach. Questions were 
asked to the entire household, with all members 
prompted to describe the events of the outbreak, any 
illness within the household, and possible contact with 
suspected cases. Two field staff recorded the answers of 
Research in context
Evidence before the study
We did a systematic review of Ebola virus seroprevalence 
surveys. We searched PubMed and Web of Science for articles 
published between Dec 1, 2013, and Dec 31, 2018, using the 
keywords “Ebola” AND “Meliandou” OR “Guinea”. We selected 
articles collecting data or describing events at the index site of 
the outbreak. No language restrictions were used. Despite 
extensive diagnostic, molecular, and phylogenetic research 
into the transmission of Ebola virus during the 2013–16 west 
African outbreak, no quantitative study or diagnostic methods 
have been employed at the suspected index location of 
Meliandou village in Guéckédou prefecture of south-eastern 
Guinea. Previous studies in this area, conducted during the 
outbreak, were necessarily limited and did not include 
serological investigation. Past studies on Ebola virus spillover 
events in other locations have relied on immunoassays with 
questionable specificity. During the west African outbreak, 
a new high specificity capture assay capable of detecting 
anti-Ebola virus immunoglobulins from oral fluid samples 
demonstrated the occurrence of mild and asymptomatic 
infections, and facilitated non-invasive serological studies 
with high population coverage.
Added value of the study
This study provides the first evidence of Ebola virus-infected 
survivors from the index site of the west African outbreak. 
A thorough retrospective epidemiological study done 
concomitantly among the resident adult population also 
greatly expands our understanding of the initiating events 
including transmission dynamics, probable transmission chains, 
lower case fatality rates, and the presence of both mild and 
asymptomatic cases.
Implications of all the available evidence
Our conclusions highlight the importance and potential of 
deploying appropriate quantitative serological tools. 
The acceptability and specificity of this approach alongside 
careful epidemiological investigation provide comprehensive 
understanding of transmission dynamics in Meliandou. 
These data thoroughly characterise the initiating events of an 
Ebola virus outbreak and show that it spread further within this 
community than previously appreciated. They also show that 
it is possible to access a large proportion of a deeply affected 
community by building up trust and using an acceptable and 
non-invasive approach.
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each participant and, after the interview, all staff discussed 
the participant responses, recording any reported 
symptoms and the maximum exposure to a suspected 
case. A maximum exposure level was assigned to every 
participant using a predetermined scale (level 1–5; 
appendix). Information for deceased individuals was 
provided by relatives living in the same household. 
Symptoms were based on Ebola virus Makona variant 
EVD case definitions, with an emphasis on symptoms 
commonly reported from the earliest clinical reports 
from the Guinea outbreak (fever, vomiting, and diarrhoea; 
appendix).1,19,24,25 At the end of the study, two further 
meetings were held with key informants (local health-
care worker, community health worker, village chief, and 
youth leader) to verify reported symptoms and to try to 
resolve any discordant information between respondents.
Permission for the study was granted by the Guinea 
Comité National D’Ethique Pour La Recherche en Santé, 
the ethics committee of the London School of Hygiene & 
Tropical Medicine, and the UK National Health Service 
National Research Ethics Service. All participants gave 
written informed consent before interviewing and 
sample collection.
Designation of suspected cases and survivors
Participants were initially denoted as being possible 
cases on the basis of symptoms reported during 
interviews (appendix). Possible cases for which clinical 
symptoms were confirmed by the key informants were 
reclassified as suspected cases (denoted by S prefix) and 
possible cases with symptoms that were not corroborated 
by key informants were designated as unconfirmed 
(denoted by U prefix). All case designations were 
determined before anti-Ebola virus IgG results were 
evaluated. Deaths during the outbreak period following 
EVD-like symptoms were classified as EVD cases.
Serological analysis
After each group interview, all adult participants 
provided an oral fluid swab using Oracol Plus collection 
devices (Malvern Medical Developments, Worcester, 
UK). Swabbing was demonstrated by field staff and 
participants were directly observed firmly rubbing the 
sponge tip along the upper and lower gums for 90 s. 
Swabs were sealed and placed on ice in a cool box. The 
same day, swabs were centrifuged at 1500 g for 10 min 
to extract oral fluid and stored immediately at –20°C. 
Swabs were transported to Conakry, Guinea, at a 
maximum temperature of –15°C and shipped to the UK 
on dry ice for analysis at Porton Down, UK. Positive 
controls of oral fluid samples were provided by two 
PCR-confirmed survivors of Ebola virus infection 
(based in Guéckédou town) with persistent neutralising 
anti-Ebola virus IgG titres recorded as part of survivor 
studies. Serum samples were also acquired from the 
positive controls, one local negative control, and two 
suspected EVD survivors from Meliandou. Four 
UK-based volunteers also provided negative control 
samples.
We detected human anti-Ebola virus (Zaire) IgG using an 
enzyme-linked immuno sorbent anti-Ebola virus glyco- 
protein IgG capture assay (Kalon Biological, Guildford, 
UK) that was developed as a commercially available assay 
from the validated assay described previously.7,26 Samples 
were thawed for 1–2 days at 4°C and centrifuged at 1500 g 
for 10 min. The supernatant was removed and diluted 1:2 in 
sterile transport media: phosphate buffer saline pH 7·4 
(Severn Biotech, Kidderminster, UK), 10% fetal calf serum 
(Gibco, Loughborough, UK), 0·5% gentamicin (Gibco), 
0·2% amphotericin B (Sigma-Aldrich, Dorset, UK), and 
0·2% Tween 20 (Sigma). All samples were run in duplicate. 
Optical density was read at 450 nm using a Spectra Max 3 
plate reader and is presented as a ratio to the optical density 
of negative controls on each plate as a normalised optical 
density.
Statistical analysis
Epidemiological data were double-entered into EpiData 
(Odense, Denmark; version 4.2.0.101) and exported into 
RStudio (version 1.0.13) for analysis. We used a generalised 
linear model (logit link function) to estimate odds ratios 
for the association of sociodemographic variables and 
exposure level with Ebola virus infection (defined as anti-
Ebola virus IgG seropositive or died of suspected EVD 
during the outbreak period). We calculated p values via 
likelihood ratio tests (packages glm version 3.4.0, epiR 
version 0.9-96, and lmtest, version 0.9-35). We adjusted 
estimates for age and maximum exposure, and assessed 
model assumptions for violations. For additional capture 
assay analysis to assess the association between sample 
volume or precipitate and normalised optical density we 
used unadjusted linear regression and Kruskall-Wallis 
non-parametric methods.
Role of the funding source
The sponsor of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data in the study and had final 
responsibility for the decision to submit for publication.
Results
Between June 22, and July 9, 2017, we enrolled 
237 participants from 27 households in Meliandou. One 
household was absent and two refused. 237 adults 
(≥18 years) were interviewed and gave swabs, of whom 
117 (49·4%) were men and 120 were women (50·6%), 
with a mean age of 29·8 years. 38 adults from 
participating families were absent for survey activities. 
The most common occupations were subsistence 
farmers (40·4%), housewives (19·8%), or students or 
unemployed (23·5%).
32 possible cases were identified via the interviews on 
the basis of reported symptoms. Of these, 13 people had 
See Online for appendix
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Figure 1: Mean NOD values 
from oral fluid samples of all 
study participants using 
anti-Ebola virus IgG 
capture assay
Samples are ranked by mean 
NOD value (except the positive 
controls). All samples were run 
in duplicate. (A) Mean NOD 
values of all samples. (B) Mean 
NOD values of samples with 
NOD >0·8, for improved 
resolution. The majority of 
a priori suspected cases 
clustered around the highest 
ranked NOD values. 
The dashed lines show NOD 
values of 1·1 and 0·9. NOD 
values >1·1 were classified as 
seropositive. NOD=normalised 
optimal density.
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died and ten were confirmed by key informants to have 
had EVD-like symptoms at the time, resulting in 
23 suspected cases (S1–23). The remaining possible cases 
with reported symptoms were not confirmed by the key 
informants (pre-fixed U01–09). Of the 23 suspected 
cases, three deaths were in children and one survivor 
with confirmed symptoms was younger than 18 years so 
no oral fluid sample was collected.
After we checked sample integrity and the volume 
extracted after centrifugation, 224 of 237 oral fluid samples 
were available for testing. During assay optimisation, the 
magnitude of normalised optical density responses in the 
positive control oral fluid samples (controls with persistent 
Ebola virus neutralising serum antibody titres) fell below 
a priori defined cutoffs for seroconversion (appendix).7 An 
alternative seropositive cutoff applied in previous Ebola 
virus seroprevalence studies27,28 was defined as the ratio of 
the optical density of the test sample to the optical density 
of four plate-specific negative controls plus three SDs of 
the mean of the negative controls. To ensure conservative 
classification of cases, only normalised optical density 
values above 1·1 were classified as seropositive. Full details 
of cutoff definitions are in the appendix, with sensitivity 
analyses varying the cutoff between 2 and 5 SDs above the 
mean of the negative controls.
Eight of 224 oral fluid samples were seropositive 
(3·57%, 95% CI 1·55–6·92) including six of the nine 
suspected cases in adults (figure 1, table 1); median 
normalised optical density 1·35), implying 7·29% 
(4·38–11·27; 18 of 247) of the total adult study population 
was infected with Ebola virus. Among the eight 
seropositive adults was one unconfirmed case with self-
reported mild nausea, vomiting, and diarrhoea (U01) and 
high exposure (level 1, direct contact with the corpse of 
someone with EVD) and one asymptomatic patient (A01) 
with low exposure (level 4, attended funerals without 
direct involvement). In the household of the only 
asymptomatic patient where no other cases were 
suspected or serologically confirmed, six other family 
members had their oral fluid sampled and all were 
negative. Mild or asymptomatic forms of Ebola virus 
infection represented 11·1% (1·46–36·44; two of 18) of 
total adult infections.
Among unconfirmed cases (U01–09), the median 
normalised optical density of oral fluid was 0·68 (95% CI 
0·67–0·70), compared with 0·71 (0·65–0·94) among all 
other oral fluid samples. Three suspected cases in which 
symptoms were confirmed (S14, S16, and S20) remained 
under the seropositive cutoff with normalised optical 
density values of 1·0, 0·73, and 0·64, respectively.
By use of interviews and a population of cases defined 
by immunoassay results, including eight anti-Ebola virus 
IgG positive survivors, all seronegative patients or 
suspected cases that were not tested, and 13 suspected 
EVD deaths (including the three children who died 
during the outbreak), we generated a transmission chain 
that affected ten households (figure 2).
The index case arose in December, 2013, in a boy aged 
2 years (S1) whose first contact with Ebola virus reservoirs 
was possibly insectivorous bats.29 The infection spread to 
his sister (S2; aged 4 years) and pregnant mother (S3) who 
shared a room with S1 while he was symptomatic. All three 
died within 2 weeks. The mother suffered a spontaneous 
abortion on the night of her death, during which she was 
cared for by family members (S4 and S7), local female 
health-care volunteers (S5, S6, S11, and S12), and a male 
local health-care worker (S18). All were heavily exposed to 
blood lost by S3 and all but S18 had close contact with the 
body immediately after death. All individuals subsequently 
developed EVD and four died (S4–S7). S4 and S5 caused 
onward transmission outside Meliandou after attending 
district hospitals.19,22 S4 was the first to develop symptoms 
but was also exposed to S1–S3 during their illness and after 
death. In Meliandou, traditional funeral practises involve 
direct contact with the deceased’s body and possessions, 
including wearing their clothes, and are performed by 
friends and family of the same sex.
While in hospital, S4 was cared for by several family 
members (S7–S10) and her body was returned to 
Meliandou for burial. The next patients, S5 and S6, were 
the first cases in individuals residing outside the home of 
the index patient. Both were buried in Meliandou within 
2 days of each other. S6’s son (S17, aged 2 years) later died 
with EVD-like symptoms. The funerals of S4–S6 are 
believed to have spread the infection to other local 
villages.19
Case definition Exposure 
level*
IgG capture 
assay†
Coefficient 
of variation 
(all wells)
Seropositive cases
S11 Suspected 1 2/2 0·04
S12 Suspected 2 2/2 0·01
S13 Suspected 2 2/2 0
S18 Suspected 1 4/4 0·02
S19 Suspected 1 2/2 0·01
S23 Suspected 2 4/4 0·07
A01 Asymptomatic 4 2/2 0·03
U01 Unconfirmed 1 4/4 0·02
Seronegative clinically suspected cases
S14 Suspected 2 0/2 <0·01
S16 Suspected 2 0/2 0·02
S20 Suspected 2 0/2 0·02
All samples with two or more capture assay wells NOD >1·1 were classified as 
seroconverted and Ebola virus survivors. The number of wells tested and the 
subsequent number with NOD values greater than 1·1 are shown alongside 
the coefficient of variation across all capture assay wells tested for each sample. 
NOD=normalised optimal density. EVD=Ebola virus disease. *Level 1, contact with 
EVD corpse; level 2. direct contact with EVD cases or their bodily fluids; level 3, 
shared household with or cared for EVD case without direct contact; level 4, 
interaction with EVD cases without contact; and level 5, no known contact. 
(appendix). †Data are positive wells/wells tested.
Table 1: Summary oral fluid immunoassay results from all clinically 
suspected survivors and seropositive oral fluid samples, by case number
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The next cases arose in the family of those caring for 
S4 during her stay in hospital and burial (S7–S10). S7, 
who also had high exposure to S3 and lived in the index 
household, was cared for in the home of a friend (S13) 
while symptomatic. S7 died and was buried in Meliandou. 
The asymptomatic seropositive patient (A01) attended 
the funeral of S7 but was not involved in the preparations 
of the body. The other family members who cared for 
S4 in hospital (S8–S10) all subsequently developed EVD 
symptoms. S8 and S10 returned to their home village 
(Dawa), where they were buried. S9 travelled to Conakry, 
where he developed symptoms and died.
Although S11 and S12, who were health-care 
volunteers, were not previously reported as EVD cases, 
both developed EVD-like symptoms (including fever, 
vomiting, and diarrhoea). S11’s son (S19) cared for her 
and developed unreported EVD-like symptoms; he 
subsequently left Meliandou to seek traditional remedies 
and survived. During the same week, S13 developed 
symptoms after caring for S7, including contact with 
body fluids, but survived without admission to hospital.
The local health-care worker (S18) developed EVD-like 
symptoms, including fever, vomiting, diarrhoea, red 
eyes, and blurry vision, but survived. He was involved 
in the care of all affected patients and in several 
burials. S18 was cared for exclusively by his wife (S23), 
who was incapacitated with EVD-like symptoms but 
survived.
Figure 2: Probable Ebola virus transmission chain based on clinical symptoms of infection and anti-Ebola virus IgG serological results
The transmission chain includes all clinically suspected cases for which symptoms were confirmed by key informants (even if seronegative or if serology was not done), all seropositive survivors, 
and all suspected EVD deaths. The most likely routes of infection are shown, based on the highest level of exposure to a patient with EVD reported during group interviews. Dashed arrows show 
multiple plausible routes of infection. Red boxes show EVD death. Green boxes show seropositive EVD survivors. White boxes show clinically suspected cases of EVD in patients who were IgG 
seronegative (S14, S16, and S20) or were too young to collect oral fluid samples (S15). Solid parentheses show multiple potential cases arising from a single source (amplification event). Dashed 
parentheses towards S18 show uncertainty of the main route of transmission due to extensive level 1–2 exposures to patients S1–S17. HH indicates the individual’s household of residence at the onset 
of symptoms. Relationships described in parentheses within each box describe the relationship of that individual to the probable source of their infection (upstream origin of arrow). HHC and HHC2 
denote different dwellings in the same household. Households denoted as HHNA were not given household suffixes because HH was assigned on the basis of the first appearance of symptoms and 
neither case developed symptoms in Meliandou. EVD=Ebola virus disease. HCW=health-care worker.
S21 Female, aged 40 years HHK
Buried (Meliandou)
U01 Female, aged 15 years 
(daughter) HHK
Survived (Meliandou)
S10 Female, aged 34 years 
(niece) HHE
Treated (Meliandou) 
Buried (Dawa)
S9 Male, aged 34 years 
(nephew) HHNA
Died (Conakry)
S8 Female, aged 40 years 
(sister) HHD
Treated (Meliandou) 
Buried (Dawa)
External transmission (other village)
S4 Female, aged 46 years 
(grandmother) HHA
Buried (Meliandou)
Amplification event
S15 Female, aged 5 years 
(daughter) HHH
Survived (Meliandou)
S13 Female, aged 37 years 
(friend) HHH
Survived (Meliandou)
A01 Male, aged 18 years 
(attended funeral) HHNA
Survived (Meliandou)
S7 Female, aged 22 years 
(sister [S3], daughter [S4]) 
HHA Buried (Meliandou)
S16 Male, aged 37 years 
(husband) HHH
Survived (Meliandou)
S22 Female, aged 21 years HHC2
Buried (Meliandou)
S17 Male, aged 2 years 
(son) HHC
Buried (Meliandou)
S14 Female, aged 27 years 
(HCW) HHI
Survived (Meliandou)
S12 Female, aged 62 years 
(HCW) HHG
Survived (Meliandou)
S11 Female, aged 62 years
(HCW) HHF
Survived (Meliandou)
S6 Female, aged 40 years
(HCW) HHC
Buried (Meliandou)
S5 Female, aged 48 years 
(HCW) HHB
Buried (Meliandou)
S19 Male, aged 42 years 
(son) HHG
Survived (left Meliandou)
S20 Female, aged 27 years 
(daughter-in-law) HHG
Survived (left Meliandou)
S23 Female, aged 42 years 
(wife) HHJ
Survived (left Meliandou)
S18 Male, aged 50 years
(HCW) HHJ
Survived (left Meliandou)
S3 Female, aged 24 years 
(mother) HHA
Buried (Meliandou)
S2 Female, aged 4 years 
(sister) HHA
Buried (Meliandou)
S1 Male, aged 2 years 
(index case) HHA
Buried (Meliandou)
Amplification event
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The last two suspected EVD deaths in Meliandou (S21 
and S22) had safe burials by health authorities and 
external non-governmental organisations (such burials 
started after March 10, 2014). S21 was probably exposed to 
Ebola virus outside Meliandou, while preparing for burial 
the body of a patient with suspected EVD in another 
village. Patient U01, who reported mild nausea, vomiting, 
and diarrhoea, cared for S21 and participated in her 
funeral. S22, who was the last individual to die, had several 
possible routes of infection: providing care in the same 
compound as S6 and S17, interacting with her symptomatic 
brother (S19), and assisting in the funeral of S7.
None of the first ten patients (S1–10) survived, after 
which only three patients died and eight survived 
(in addition to three who were seronegative and a child 
who was not tested; table 2). Among adults, and including 
only those who were seropositive as survivors, case fatality 
was 55·6% (95% CI 30·8–78·5; ten of 18 participants); 
with the inclusion of three children, this value was 
61·9%, excluding potential survivors and mildly 
symptomatic cases in children.
Among adult participants (237 interviewed and ten 
EVD deaths), 92 reported high-level exposure to suspected 
cases (61 at level 1, 31 at level 2), with a further 45 sharing 
Age, years* Sex Household Probable exposure Died Previously 
reported case†
Seropositive
S1 2 Male A Insectivorous bats29 Yes Yes NA
S2 4 Female A Shared bed with S1 Yes Yes NA
S3 24 Female A Shared room and cared for S1 and S2 Yes Yes NA
S4 46 Female A Shared bed with S1 and S2; cared for S1, S2, 
and S3; attended burials of S1–S3
Yes Yes NA
S5 48 Female B Cared for S3 during spontaneous abortion; 
participated in burials of S3 and S4
Yes Yes NA
S6 40 Female C Cared for S3 during spontaneous abortion; 
participated in burials of S3 and S4
Yes Yes NA
S7 22 Female A2 Cared for S3 during spontaneous abortion; 
cared for S4 in hospital; participated in burial 
of S4
Yes Yes NA
S8 40 Female D Cared for S4 in hospital (sister); participated 
in burial of S4
Yes Yes NA
S9 34 Male NA Cared for S4 in hospital (nephew); 
participated in burials of S3 and S4
Yes Yes NA
S10 34 Female E Cared for S4 in hospital (niece); participated 
in burial of S4
Yes Yes NA
S11 62 Female F Cared for S3 during spontaneous abortion; 
participated in burials of S3 and S4
No No Yes
S12 62 Female G Cared for S3 during spontaneous abortion; 
cared for S4 when ill
No No Yes
S13 37 Female H Cared for S7 in their home when ill No No Yes
S14 27 Female I Cared for S7 with traditional medicine No No No
S15 5 Female H Shared home and cared for S13 No No NA
S16 37 Male H Cared for S13 and S15 when ill No No No
S17 2 Male C Shared room with S6 Yes Yes NA
S18 50 Male J Provided medical care for S1–S17; cared for 
S3 during spontaneous abortion
No No Yes
S19 42 Male G Cared for S12 when ill No No Yes
S20 27 Female G Cared for S12 when ill No No No
S21 40 Female K Prepared body of suspected case in nearby 
village
Yes No NA
S22 21 Female C2 Transmission not clear; cared for a 
participated in burial of S6, participated in 
burial of S7, and shared household with S17
Yes No NA
S23 42 Female J Cared for S18 when ill No No Yes
U01 15 Female K Cared for S21 when ill No No Yes
A01 18 Male NA Attended funeral of S7 No No Yes
Suspected cases were those in which patients reported at least three symptoms of Ebola virus disease during the outbreak period whose symptoms were confirmed by key 
informants or who died following Ebola virus disease-like symptoms. Also included are two individuals who were seropositive for anti-Ebola virus IgG whose self-reported 
mild symptoms were unconfirmed by key informants (U01) or were self-reported asymptomatic (A01). NA=not applicable. *At the time of the outbreak. †Reported in 
publicly available reports from a previous outbreak investigation.19,22
Table 2: Clinically suspected or seropositive cases identified during epidemiological investigation, by case number
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residence or providing care for a symptomatic patient 
without direct contact (level 3; table 3). All EVD deaths 
and seropositive patients with symptomatic EVD reported 
level 1 or level 2 exposure. The asymptomatic patient 
(A01) reported level 4 exposure. Strong evidence was 
found for a linear association of exposure level with Ebola 
virus infection (cases or deaths, table 3; univariable 
OR 2·82, 1·66–4·79; p<0·0001). This value was similar 
after adjustment for age (adjusted OR 2·68, 1·50–4·80) 
and for age and health-care role (adjusted OR 2·79, 
1·59–4·88). The risk of Ebola virus infection was similar 
after either level 1 or level 2 exposure (table 3).
In the univariable analysis, Ebola virus infection was 
most common among women, with increasing age, and 
in those with a formal or informal health-care 
responsibility in the community (table 3). After 
adjustment for age and exposure level, health-care 
responsibilities remained an independent risk factor for 
Ebola virus infection (OR 6·64, 1·54–28·56; p=0·001). 
There was no effect of age after adjusting for exposure 
level, or of sex after health-care workers were removed 
from the full model (table 3). A sensitivity risk factor 
analysis with alternative cutoff values is shown in the 
appendix.
Discussion
This cross-sectional seroprevalence survey used detailed 
investigation and non-invasive immunological tools to 
document Ebola virus transmission at the index site of 
the largest recorded outbreak of human EVD. Although 
an outbreak investigation was done in 2014, no 
diagnostic or immunological methods have been 
previously used in Meliandou.19 Our study adds to past 
investigations, highlighting a much greater spread of 
infection, including an increased number of reported 
deaths (13 vs 11) and the identification of eight 
seropositive survivors. Although initial zoonotic and 
human-to-human transmission within the index 
household have already been documented,19,29 our 
account of subsequent events differs notably, particularly 
in the wider impact of the virus among households not 
directly related to the index case and the identification 
of mildly symptomatic and asymptomatic survivors. 
From a public health perspective, these findings 
highlight the need for community-sensitive approaches 
to enhance case finding during spillover events, and the 
potential of non-invasive tests to aid community 
participation and gain a better understanding of 
infection spread.
Cases, n/N Risk (95% CI) Univariate OR p value OR adjusted for age 
and exposure level
p value
Total 18/247 7·29 (4·38–11·28) ·· ·· ·· ··
Sex
Male 4/118 3·39 (0·93–8·45) 1 0·02 1 0·09
Female 14/129 10·85 (6·06–17·54) 3·47 (1·10–10·86) ·· 2·64 (0·80–8·66) ··
Age, years
15–25 5/128 3·91 (1·28–2·88) 1·03 (1·00–1·06) 0·05 1·00 (0·97–1·03) 0·82
25–40 6/62 9·68 (3·63–19·88) ·· ·· ·· ··
>40 7/57 12·23 (5·08–23·68) ·· ·· ·· ··
Head of family unit
Yes 2/44 4·54 (0·56–15·47) 0·56 (0·12–2·51) 0·42 0·31 (0·06–1·56) 0·12
No 16/203 7·88 (4·58–12·48) 1 ·· ·· ··
Occupation
Other or unemployed 8/187 4·28 (1·86–8·23) 1 0·13 1 0·38
Housewife 5/49 10·20 (3·40–22·23) 2·54 (0·79–8·15) ·· 1·76 (0·51–6·06) ··
Health-care role in village (including traditional)
No 13/234 5·56 (2·99–9·31) 1 0·0003 1 0·001
Yes 5/11 45·45 (16·75–76·62) 14·29 (3·85–53·08) ·· 6·64 (1·54–28·56) ··
Maximum exposure to EVD case
Level 1 11/61 18·03 (9·36–29·98) 2·82 (1·66–4·79) <0·0001 2·79 (1·59–4·883) <0·0001
Level 2 6/31 19·35 (7·45–37·47) ·· ·· ·· ··
Level 3 0/45 0 (0–7·87) ·· ·· ·· ··
Level 4 1/87 1·49 (0·03–6·24) ·· ·· ·· ··
Level 5 0/23 0 (0–14·81) ·· ·· ·· ··
Cases are defined as seropositive for anti-Ebola virus IgG or suspected EVD deaths. We used a generalised linear model with a logit function to calculate crude estimates; 
p values were calculated via likelihood ratio test. The association with exposure level persisted after additionally adjusting for health-care work (adjusted OR 2·80, 95% CI 
1·48–5·31). For sex, the association was lost when health-care workers were removed from the analysis (2·25, 0·58–8·77). Data were missing for occupation (n=11) and 
health-care role (n=2). EVD=Ebola virus disease. OR=odds ratio.
Table 3: Risk factors for Ebola virus infection in the Meliandou population (aged ≥18 years)
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Identifying survivors enhances our understanding of 
the transmission dynamics of Ebola virus during this 
spillover event. After the initial cases in the index family, 
the virus propagated across numerous households, 
stemming from a series of high-level exposures to cases 
in the absence of any preventive interventions. Both 
traditional funeral practices and contact with sympto-
matic patients or their body fluids were important in the 
dissemination of Ebola virus infection, as was also 
reported in rural areas during the course of the wider 
outbreak.30 The involve ment of formal and informal 
health-care workers in caring for S3 during her 
spontaneous abortion and death acted as an amplification 
event, spreading the infection to other households. The 
early involvement of local health-care workers in the 
outbreak draws parallels to many previous Ebola virus 
spillover events.31
We found evidence of asymptomatic and minimally 
symptomatic cases of Ebola virus infection in Meliandou, 
adding to the evidence on the prevalence of these disease 
states during the west Africa outbreak.7,10 Although we 
have reported a case as asymptomatic infection, it is 
challenging to be sure retrospectively that there were no 
symptoms. Although onward transmission from asymp- 
tomatic infection cannot be ruled out, we found no 
evidence of further infection within the household of the 
asymptomatic case. Notably, three suspected cases did not 
self-report symptoms but were identified as symptomatic 
by key informants. The use of key informants was, 
therefore, crucial in preventing mis classification of cases 
as asymptomatic, and is relevant to future studies because 
of the persistent stigma around EVD.
The case fatality (55·6% in adults, 61·9% including 
three children aged <18 years) in Meliandou was lower 
than previously reported (100%).19 The value for children 
could be overestimated owing to the exclusion of infected 
children with mild or no symptoms. These values are 
closer to the case fatality of 70·7% among patients with 
clinically suspected EVD during the early stages of the 
outbreak.25 Despite some Meliandou patients receiving 
hospital treatment (S4, S5, and S9), Ebola virus was not 
recognised as the causative agent until March 23, 2014, 
and patients did not receive targeted treatment.18 The 
case fatality is therefore perhaps lower than might be 
anticipated given a case fatality of 88·8% among patients 
not receiving hospital treatment during the initial stages 
of the outbreak,1,25,32 but can be explained by the inclusion 
of two patients who would not have been recognised at 
the time. There was some evidence that the case fatality 
waned over the course of the outbreak in Meliandou.33 
This observation is unlikely to be due to differences in 
exposure because, unlike attack rates, intensity of 
exposure has previously been shown not to correlate with 
case fatality.33 It could be explained through differences 
in the incubation period (the more susceptible getting ill 
quicker and being more likely to die), genetic 
susceptibility, or chance.
The use of a non-invasive immunoassay based on oral 
fluid to detect anti-Ebola virus IgG was acceptable to the 
community and ensured high participation. Although the 
assay was previously validated in a comparable setting,7 
we saw changes in the assay’s performance that required 
changes in the study cutoff. Between studies, the assay 
was moved to a commercial manufacturer and a different 
swab was used, which could explain the differences 
(appendix). Oral fluid samples used with this capture 
assay have a reduced titre relative to plasma, yet still 
reflect the plasma concentration of IgG with a linear 
relationship.34 As this study is the first to report the use of 
oral fluid to detect anti-Ebola virus IgG over 3 years since 
initial infection, it is possible that waning IgG titres 
might contribute to reduced magnitude responses. 
Previous reports have suggested that serum anti-Ebola 
virus IgG titres can decrease over time, although this 
hypothesis has never been comprehensively addressed,28 
and persistent IgG titres, including Ebola virus neu-
tralising capacity, have been detected 11–40 years after 
infection.27,35 Despite challenges, our study conclusions 
are robust to variations in the chosen cutoff. Increasing 
the cutoff to 4 SDs above the mean produced identical 
results, yet increasing above 5 SDs excluded cases with 
high live Ebola virus plasma neutralising antibody titre, 
so appears too stringent. Lowering the cutoff included 
one further asymptomatic patient, while removal of all 
cases falling between 2 SD and 5 SD cutoffs only mildly 
affected the strength of risk factor associations. Although 
the use of UK-based negative controls could be considered 
a limitation of the immunoassays, adherence to previous 
protocols and cutoff sensitivity analysis reinforces the 
specificity of our findings. Given the loss of several 
samples owing to low volume oral fluid, we caution future 
studies against using oral fluid devices that require 
centrifugation to extract oral fluid.
This study has important limitations. Owing to the 
time that has elapsed since the outbreak, recall bias is 
likely, and is only partly offset by using group interviews 
and key informants. Serology was restricted to adults 
(aged ≥18 years), so children who had mild or no 
symptoms might have been missed, which under-
estimates these disease states.
Our findings from Meliandou provide important 
documentation of the initiating events of the 
2013–16 outbreak of Ebola virus in west Africa. Future 
research into Ebola virus and other emerging diseases 
will benefit from the use of acceptable non-invasive 
sampling to further our knowledge of mild and 
asymptomatic infection and transmission among 
populations at risk of Ebola virus spillover events. Such 
information can improve our understanding of the 
natural history of Ebola virus and contribute to 
establishing appropriate and sustainable surveillance 
systems to prevent communities like Meliandou from 
suffering the long-term effects of Ebola virus and related 
outbreaks.
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